| Print
Grace Therapeutics Inc (GRCE)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
Address
545 Promenade du Centropolis
Suite 100
Laval
QC
CAN
H7T 0A3
Telephone
+1 450 6864555
Forecast key dates
| Name | Key Date |
|---|---|
| Grace Therapeutics Inc Second Quarter Earnings Results for 2027 | 2026-11-13T00:00:00 |
| Grace Therapeutics Inc First Quarter Earnings Results for 2027 | 2026-08-12T00:00:00 |
| Grace Therapeutics Inc Fourth Quarter Earnings Results for 2026 | 2026-06-23T00:00:00 |
| Grace Therapeutics Inc Annual Report for 2026 | 2026-06-23T00:00:00 |
| Grace Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-02-13T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Grace Therapeutics Inc Second Quarter Earnings Results for 2026 | 2025-11-13T00:00:00 |
| Grace Therapeutics Inc Annual General Meeting for 2025 | 2025-09-12T08:30:00 |
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08T00:00:00 |
| Grace Therapeutics Inc First Quarter Earnings Results for 2026 | 2025-08-12T00:00:00 |
| Grace Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2025-06-23T00:00:00 |
| Grace Therapeutics Inc Annual Report for 2025 | 2025-06-23T00:00:00 |
| TD Cowen 45th Annual Health Care Conference | 2025-03-04T14:30:00 |
| Grace Therapeutics Inc Third Quarter Earnings Results for 2025 | 2025-02-13T00:00:00 |
| 14th Annual LifeSci Partners Corporate Access Event | 2025-01-13T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.